课题基金 / 基金详情

HIV Vaccine Design and Development Team

HIV Vaccine Design and Development Team
HIV疫苗设计和开发团队
批准号:
6348770
负责人:
PAUL J MADDON
金额:
$197.43万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-09-30 至 2002-09-29

项目摘要

项目成果

PAUL J MADDON的其他基金

相似基金

相关文献

中文摘要
翻译
这项建议的总体目标是开发一种疫苗并将其用于人体临床试验,该疫苗可诱导能广泛中和原发HIV分离株的抗体。作为多组分疫苗策略的一部分,有效的抗病毒抗体反应是预防性艾滋病毒疫苗补充广泛活性细胞免疫反应的理想特征。我们的疫苗概念是创造寡聚HIV包膜糖蛋白(env)复合物,提供病毒相关env的真实抗原模拟物。虽然这一直是HIV疫苗研究的长期目标,但由于gp120和gp41之间非共价相互作用的固有不稳定性,真正的低聚物从未作为重组蛋白生产出来。然而,我们实验室最近的发现表明,这一限制可以通过在两个亚基蛋白之间引入二硫键来克服。正如我们在下文(以及Binley等人的文章)中所描述的那样。当引入的半胱氨酸残基被放置在有利位置时,gp120和gp41形成稳定的寡聚复合物,其抗体反应性模式与病毒相关的env相似。通过稳定地将这种抗原相关结构呈现给免疫系统,这种免疫原原则上可以诱导中和抗体反应,优于上一代基于env的疫苗或自然感染所引起的反应。我们的主要方法是基于这一概念开发一种重组低聚HIV亚单位疫苗。目前,亚单位疫苗通过以均匀、浓缩和最佳佐剂形式递送免疫原,提供了诱导强大的体液免疫反应的最有效手段。然而,我们认识到其他方法可能提供将低聚物输送到人体系统的更好方法。因此,我们还将研究基于核酸的疫苗方法,其中低聚物是在体内合成的。为此,我们与AlphaVax, Inc.合作开发了基于委内瑞拉马脑炎(VEE)病毒的非复制病毒载体。虽然我们的主要目标是诱导有效的抗病毒抗体反应,但我们也将研究亚基和病毒疫苗引起的细胞免疫反应,以指导我们为进一步开发选择最佳结构。我们的项目包括一个广泛的和迭代的计划,设计和测试这些新的免疫原在最好的体外和HIV感染动物模型中,包括shiv -猕猴模型。我们力求研制一种安全有效的艾滋病毒疫苗,供全世界用于遏制艾滋病的流行。因此,我们工作的一个主要和早期重点将是基于源自C亚型病毒的envs制备候选疫苗。最有希望的候选疫苗将在南非和美国的I/II期人体临床试验中进行测试。我们的重点是,基于开发的方法将由来自两个行业的具有疫苗设计,开发和临床测试各个方面经验的杰出研究人员组成的联盟进行。
英文摘要
The overall goal of this proposal is to develop and bring to human clinical testing a vaccine which induces antibodies that potently and broadly neutralized primary HIV isolates. An effective antiviral antibody response is a desirable feature of prophylactic HIV vaccine to supplement broadly active cellular immune responses as part of a multi-component vaccine strategy. Our vaccine concept is to create oligomeric HIV envelope glycoprotein (env) complexes that provide authentic antigenic mimics of virus-associated env. Although this has been a long-standing goal of HIV vaccine research, authentic oligomers have never been produced as recombinant proteins due to the inherent instability of the non-covalent interaction between gp120 and gp41. However, recent findings in our laboratories demonstrate that this limitation can be overcome by introducing a disulfide bond between the two subunit proteins. As we describe below (and in the Binley et al. Manuscript included in the Appendix), when the introduced cysteine residues are placed in favorable locations, gp120 and gp41 form a stable oligomeric complex whose pattern of antibody reactivity mirrors that of virus- associated env. By stably presenting this antigenically relevant structure to the immune system, this immunogen could in principle induce a neutralizing antibody response superior to that elicited by prior generation env-based vaccines or by natural infection. Our primary approach is to develop a recombinant oligomeric HIV subunit vaccine based on this concept. At present, subunit vaccines provide the most effective means of inducing robust humoral immune responses by delivering the immunogen in a homogeneous, concentrated, and optimally adjuvanted form. However, we recognize that other approaches may provide superior means of delivering the oligomers to the human system. Therefore, we will also examine a nucleic acid-based vaccine approach wherein the oligomers are synthesized in vivo. For this, we have teamed with AlphaVax, Inc. who have developed non- replicating viral vectors based on the Venezuelan Equine Encephalitis (VEE) virus. Although our primary goal is to induce an effective antiviral antibody response, we will also examine cellular immune response elicited by both the subunit and viral vaccines to guide our selection of the optimum construct(s) for further development. Our projects includes an extensive and iterative program for designing and testing these novel immunogens in the best available in vitro and animal models of HIV infection, including the SHIV-macaque model. We seek to develop a safe and efficacious vaccine against HIV for worldwide use in stemming the AIDS epidemic. Therefore, a primary and early focus of our effort will be to prepare vaccine candidates based on envs derived from subtype C viruses. The most promising vaccine candidates will be tested in Phase I/II human clinical trials in both South African and the U.S. Our focused, development-based approach will be carried out by a consortia of distinguished investigators from both industry with experience in all aspects of vaccine design, development and clinical testing.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CCR5 inhibitors that block HIV but not chemokines
  • 批准号:
    6746752
  • 项目类别:
  • 资助金额:
    $30.36万
  • 财政年份:
    2004
  • 负责人:
    PAUL J MADDON
  • 依托单位:
Development of Small-Molecule HIV Entry Inhibitors
  • 批准号:
    6698946
  • 项目类别:
  • 资助金额:
    $89.94万
  • 财政年份:
    2001
  • 负责人:
    PAUL J MADDON
  • 依托单位:
HIV Vaccine Design and Development Team
  • 批准号:
    6374728
  • 项目类别:
  • 资助金额:
    $209.05万
  • 财政年份:
    2000
  • 负责人:
    PAUL J MADDON
  • 依托单位:
CLINICAL TRIALS OF CD4 IGG2 AND HUMAB COMBINATIONS
  • 批准号:
    2887738
  • 项目类别:
  • 资助金额:
    $54.6万
  • 财政年份:
    1998
  • 负责人:
    PAUL J MADDON
  • 依托单位:
海外基金